Tech Company Financing Transactions
Clarametyx Biosciences Funding Round
On 1/6/2024, Clarametyx Biosciences received $33 million in Series A funding from Ohio Innovation Fund, 1776 and JobsOhio Growth Capital Fund.
Transaction Overview
Company Name
Announced On
1/6/2024
Transaction Type
Venture Equity
Amount
$33,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to accelerate efforts across its pipeline, including specifically to evaluate the potential of its lead therapeutic candidate CMTX-101 to combat infection in people with cystic fibrosis (CF), a progressive, genetic disease that affects the lungs, pancreas and other organs.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
1275 Kinnear Road
Columbus, OH 43212
USA
Columbus, OH 43212
USA
Phone
Website
Email Address
Overview
Clarametyx Biosciences Inc. is a clinical stage biotechnology company developing immune-enabling biologic therapies to fight life-threatening infections. Our novel technology platform targets the protective barrier around bacteria, known as biofilms.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Richards
Chief Operating Officer
Veronica Hall
Chief Scientific Officer
Charles McOsker
VP - Operations
Teresa Byrne
Browse more venture capital transactions:
Prev: 1/6/2024: Credo Health Solutions venture capital transaction
Next: 1/7/2024: Isomorphic Labs venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs